First Bank & Trust Purchases 19,484 Shares of GSK PLC Sponsored ADR $GSK

First Bank & Trust grew its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 61.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,151 shares of the pharmaceutical company’s stock after purchasing an additional 19,484 shares during the period. First Bank & Trust’s holdings in GSK were worth $2,208,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC purchased a new stake in GSK in the fourth quarter valued at $528,000. Charles Schwab Investment Management Inc. raised its holdings in shares of GSK by 35.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 171,145 shares of the pharmaceutical company’s stock valued at $6,630,000 after acquiring an additional 44,498 shares during the last quarter. Deutsche Bank AG lifted its position in shares of GSK by 23.7% in the first quarter. Deutsche Bank AG now owns 9,496 shares of the pharmaceutical company’s stock valued at $368,000 after acquiring an additional 1,820 shares in the last quarter. Nuveen LLC acquired a new stake in GSK during the 1st quarter worth $1,456,000. Finally, American Century Companies Inc. boosted its position in GSK by 8.0% during the first quarter. American Century Companies Inc. now owns 704,836 shares of the pharmaceutical company’s stock worth $27,305,000 after acquiring an additional 51,971 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

GSK has been the subject of several analyst reports. Weiss Ratings reiterated a “buy (b)” rating on shares of GSK in a research report on Monday, December 15th. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research report on Monday, October 27th. HSBC reiterated a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. Finally, Cfra set a $53.00 target price on shares of GSK in a research report on Thursday, October 30th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $44.13.

GSK Price Performance

GSK stock opened at $48.58 on Friday. The stock has a market capitalization of $99.07 billion, a P/E ratio of 13.72, a P/E/G ratio of 1.32 and a beta of 0.45. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $49.44. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.84 and a quick ratio of 0.55. The firm’s 50-day moving average is $46.81 and its two-hundred day moving average is $42.13.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.GSK’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.50 EPS. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Equities analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be issued a dividend of $0.4171 per share. The ex-dividend date is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.4%. GSK’s payout ratio is presently 46.33%.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk bought 1,470,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the purchase, the insider owned 18,245,691 shares in the company, valued at approximately $346,668,129. The trade was a 8.76% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.